LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.28 2.4

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.28

Max

1.28

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 68M
Vorheriger Eröffnungskurs	-1.12
Vorheriger Schlusskurs	1.28

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Feb. 2026, 17:37 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20. Feb. 2026, 16:18 UTC

Wichtige Markttreiber

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20. Feb. 2026, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. Feb. 2026, 22:12 UTC

Ergebnisse

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. Feb. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Feb. 2026, 21:23 UTC

Ergebnisse

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. Feb. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. Feb. 2026, 21:01 UTC

Akquisitionen, Fusionen, Übernahmen

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. Feb. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20. Feb. 2026, 20:17 UTC

Market Talk

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20. Feb. 2026, 20:11 UTC

Market Talk

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20. Feb. 2026, 19:59 UTC

Market Talk

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20. Feb. 2026, 19:58 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20. Feb. 2026, 19:49 UTC

Market Talk

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20. Feb. 2026, 19:09 UTC

Market Talk

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20. Feb. 2026, 19:00 UTC

Market Talk

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20. Feb. 2026, 18:28 UTC

Market Talk

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20. Feb. 2026, 18:20 UTC

Market Talk

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20. Feb. 2026, 18:05 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. Feb. 2026, 18:04 UTC

Market Talk

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20. Feb. 2026, 17:38 UTC

Market Talk

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20. Feb. 2026, 17:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Feb. 2026, 17:24 UTC

Market Talk

Correction to Treasury Yields Fall Market Talk

20. Feb. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

20. Feb. 2026, 16:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. Feb. 2026, 16:53 UTC

Market Talk

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20. Feb. 2026, 16:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Feb. 2026, 16:45 UTC

Market Talk

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20. Feb. 2026, 16:40 UTC

Market Talk

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.